Overall verdict
Neutral
4.0/10
1-year performance
-40.49%
Score breakdown
Down 40.5% over 1 year, 3% of the 52-week range.
8 analysts, target +2.0% vs the price.
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States. Its Silence and Replace, a DNA-directedRNA interference platform, that combines RNA interference with gene therapy to create medicines which simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct.
The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene, which is in phase 1b/2a for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
Sector
Health Care
Industry
Biotechnology
Primary listing
Nasdaq
United States
CEO
Jerel Banks
Founded
—
Employees
24
Revenue / employee
0 USD
Next earnings
February 12, 2027 (estimated)
Institutional holders
- BlackRock, Inc.3.95%
- GEODE CAPITAL MANAGEMENT, LLC1.84%
- STATE STREET CORP1.18%
- GOLDMAN SACHS GROUP INC0.54%
- Bank of New York Mellon Corp0.17%
- MORGAN STANLEY0.12%
- JPMORGAN CHASE & CO0.03%
- FMR LLC0.02%
- Rest of the register92.15%
8 13F filings as of September 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
14.39 USD
52-week low
7.72 USD
1-year performance
-40.49%
Declining
Year-to-date performance
-41.84%
Declining
Drawdown
-45.00%
Major drawdown
Position in the 52-week range
3% of range
Against the world ETF
Over 12 years, from June 2014 to October 2026, the share did clearly worse than the world ETF once risk is accounted for. It earned less, while shaking 5.8 times harder.
$10,000 placed at the end of June 2014 are worth today
| Benitec Biopharma | $16 |
| World ETF | $34,964 |
| S&P 500 | $47,341 |
| Risk-free placement | $12,827 |
The risk
- Shaking:the share moves 5.8 times as much as the world ETF.
- Worst fall:-100Â % between June 2014 and January 2024. $10,000 placed at the top fell to $5. The world ETF, at worst: -34Â %. The share has not returned to its high yet.
Benitec Biopharma earned less than the world ETF since 2014
Value of $10,000 placed at the end of June 2014, dividends reinvested, in dollars
- Benitec Biopharma: $16
- World ETF: $34,964
- S&P 500: $47,341
- Risk-free placement: $12,827
Share price without dividends; the world ETF and the index reinvest theirs. A dividend payer is therefore understated here.
Based on past performance. This is not a recommendation.
ROIC -37.5%, ROE -37.6%.
Net margin
—
Sector -213.59%|S&P 13.35%
Gross margin
—
Return on equity (ROE)
-37.61%
Negative
Sector -55.92%|S&P 16.98%
Return on invested capital (ROIC)
-37.54%
Negative
Free cash flow margin (FCF)
—
Growth
0.0/10Revenue down 42.2% over 1 year, -100.0% a year over 5.
Revenue (trailing 12 months)
0 USD
Revenue growth (1y)
-42.16%
Declining
Revenue growth (3y)
-100.00%
Declining
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
—
Valuation
0.0/10The company loses money, so no valuation multiple can be read: a negative P/E is not a discount.
P/E (TTM)
—
N/A (loss)
Sector 11.0x|S&P 22.1x
Forward P/E (adjusted)
—
N/A (loss)
EV / EBITDA
—
N/A (loss)
Sector 16.5x|S&P 14.9x
PEG
—
Sector 0.38|S&P 0.84
Market cap
286M USD
Financial strength
10.0/10Cash covers 27489.4% of the debt, no net debt (net cash).
Net debt / EBITDA
—
Gearing (net debt / equity)
-103.65%
Net cash
Cash
176M USD
Cash / market cap
61.73%
Very solid
Cash / total debt
27489.41%
Net cash
Net debt
-176M USD
Equity
170M USD
Closed daily candles, 2 years
Last close on November 20, 2026: 7.92 USD
- MM208.79
- MM509.25
- MM20011.28
- RSI 1438.1
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
-3.07%
200-day average slope, 3 months
-7.01%
50-day average slope, 1 month
-15.12%
Price structure
Lower lows
Bullish RSI divergence
No
20-day volatility
4.52 % per day
Volatility change
+33.46%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2027 | -1.19 (7) | — | 0 (6) | — | -62 (4) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of November 16, 2026.
Same sub-industry: 797 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ALERS | 4.5 | 4.5 | 284M USD | 36.9x | 4.2 % | 9.1 % | 3.7 % | -0.1x | 2.0 % | 8.2 % | ||
| 2 | BNTC | 4.0 | N/A | 286M USD | Not meaningful (loss) | — | -42.2 % | -37.5 % | — | -6.2 % | -40.5 % | ||
| 3 | SPRY | 2.7 | 3.0 | 298M USD | Not meaningful (loss) | -163.6 % | 16.0 % | -112.7 % | 0.1x | -61.5 % | -59.0 % | ||
| 4 | 7630 | 2.7 | 2.7 | 292M USD | Not meaningful (loss) | -213.6 % | 14.1 % | -60.5 % | 5.4x | -4.8 % | -77.2 % | ||
| 5 | 4894 | 2.1 | 1.5 | 296M USD | Not meaningful (loss) | -1478.4 % | -52.6 % | -15.8 % | 5.0x | — | -13.8 % | ||
| 6 | EVMN | 2.1 | 0.9 | 291M USD | Not meaningful (loss) | — | -100.0 % | -68.1 % | 1.3x | -31.3 % | -63.4 % | ||
| 7 | 6945 | 1.5 | N/A | 287M USD | Not meaningful (loss) | — | — | -22.4 % | 4.5x | -4.1 % | -7.9 % | ||
| 8 | GLSI | 1.5 | N/A | 283M USD | Not meaningful (loss) | — | — | -10656.2 % | 0.3x | -4.5 % | 134.2 % | ||
| 9 | 2617 | 1.5 | N/A | 294M USD | Not meaningful (loss) | -738.1 % | — | -36.0 % | 3.6x | -12.3 % | -96.8 % |
